Vir Biotechnology (VIR) Cash from Operations (2018 - 2026)

Vir Biotechnology has reported Cash from Operations for 9 years, with the latest figure at 132386000.0 in Q1 2026.

• Quarterly Cash from Operations fell 69.47% year-over-year to 132386000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 446051000.0 (down 7.46% YoY) and the FY2025 annual result came in at 391781000.0, up 12.23% from the prior year.
• Cash from Operations declined to 132386000.0 in Q1 2026 per VIR's latest filing, from 25876000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 960136000.0 in Q2 2022 and troughed at 389247000.0 in Q2 2023.
• A 5-year average of 5061823.53 and a median of 107927000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 714.43% in 2022, then plunged 407.26% in 2023.
• Over 5 years, Cash from Operations stood at 35126000.0 in 2022, then slumped by 407.26% to 107927000.0 in 2023, then rose by 18.8% to 87635000.0 in 2024, then jumped by 70.47% to 25876000.0 in 2025, then tumbled by 411.62% to 132386000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 132386000.0, 25876000.0, and 167570000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.